Yancopoulos, G.D. et al. Vascular-specific growth factors and blood vessel formation. Nature407, 242–248 (2000). ArticleCASPubMed Google Scholar
Ferrara, N. VEGF and the quest for tumour angiogenesis factors. Nat. Rev. Cancer2, 795–803 (2002). ArticleCASPubMed Google Scholar
Ferrara, N. & Alitalo, K. Clinical applications of angiogenic growth factors and their inhibitors. Nat. Med.5, 1359–1364 (1999). ArticleCASPubMed Google Scholar
Ferrara, N. & Davis-Smyth, T. The biology of vascular endothelial growth factor. Endocr. Rev.18, 4–25 (1997). ArticleCASPubMed Google Scholar
Neufeld, G., Cohen, T., Gengrinovitch, S. & Poltorak, Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J.13, 9–22 (1999). ArticleCASPubMed Google Scholar
Karkkainen, M.J., Makinen, T. & Alitalo, K. Lymphatic endothelium: a new frontier of metastasis research. Nat. Cell Biol.4, E2–E5 (2002). ArticleCASPubMed Google Scholar
Leung, D.W., Cachianes, G., Kuang, W.J., Goeddel, D.V. & Ferrara, N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science246, 1306–1309 (1989). ArticleCASPubMed Google Scholar
Plouet, J., Schilling, J. & Gospodarowicz, D. Isolation and characterization of a newly identified endothelial cell mitogen produced by AtT20 cells. EMBO J.8, 3801–3808 (1989). ArticleCASPubMedPubMed Central Google Scholar
Nagy, J.A. et al. Vascular permeability factor/vascular endothelial growth factor induces lymphangiogenesis as well as angiogenesis. J. Exp. Med.196, 1497–1506 (2002). ArticleCASPubMedPubMed Central Google Scholar
Matsumoto, T. & Claesson-Welsh, L. VEGF receptor signal transduction. Science STKE112 (RE21), 1–17 (2001). Google Scholar
Compernolle, V. et al. Loss of HIF-2α and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice. Nat. Med.8, 702–710 (2002). ArticleCASPubMed Google Scholar
Gerber, H.P., Dixit, V. & Ferrara, N. Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J. Biol. Chem.273, 13313–13316 (1998). ArticleCASPubMed Google Scholar
Gerber, H.P. et al. VEGF regulates endothelial cell survival by the PI3-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J. Biol. Chem.273, 30366–30343 (1998). Article Google Scholar
Benjamin, L.E., Golijanin, D., Itin, A., Pode, D. & Keshet, E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J. Clin. Invest.103, 159–165 (1999). ArticleCASPubMedPubMed Central Google Scholar
Yuan, F. et al. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc. Natl. Acad. Sci. USA93, 14765–14770 (1996). ArticleCASPubMedPubMed Central Google Scholar
Gerber, H.P. et al. VEGF is required for growth and survival in neonatal mice. Development126, 1149–1159 (1999). ArticleCASPubMed Google Scholar
Clauss, M. et al. Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J. Exp. Med.172, 1535–1545 (1990). ArticleCASPubMed Google Scholar
Broxmeyer, H.E. et al. Myeloid progenitor cell regulatory effects of vascular endothelial cell growth factor. Int. J. Hematol.62, 203–215 (1995). ArticleCASPubMed Google Scholar
Gabrilovich, D.I. et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med.2, 1096–1103 (1996). ArticleCASPubMed Google Scholar
Hattori, K. et al. Vascular endothelial growth factor and angiopoietin-1 stimulate postnatal hematopoiesis by recruitment of vasculogenic and hematopoietic stem cells. J. Exp Med.193, 1005–1014 (2001). ArticleCASPubMedPubMed Central Google Scholar
Gerber, H.-P. et al. Vascular endothelial growth factor regulates hematopoietic stem cell survival by an internal autocrine loop mechanism. Nature417, 954–958 (2002). ArticleCASPubMed Google Scholar
Senger, D.R. et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science219, 983–985 (1983). ArticleCASPubMed Google Scholar
Dvorak, H.F., Brown, L.F., Detmar, M. & Dvorak, A.M. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am. J. Pathol.146, 1029–1039 (1995). CASPubMedPubMed Central Google Scholar
Bates, D.O. & Curry, F.E. Vascular endothelial growth factor increases microvascular permeability via a Ca(2+)-dependent pathway. Am. J. Physiol.273, H687–H694 (1997). ArticleCASPubMed Google Scholar
Roberts, W.G. & Palade, G.E. Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. J. Cell Sci.108, 2369–2379 (1995). ArticleCASPubMed Google Scholar
Ku, D.D., Zaleski, J.K., Liu, S. & Brock, T.A. Vascular endothelial growth factor induces EDRF-dependent relaxation in coronary arteries. Am. J. Physiol.265, H586–H592 (1993). CASPubMed Google Scholar
Yang, R. et al. Effects of vascular endothelial growth factor on hemodynamics and cardiac performance. J. Cardiovasc. Pharmacol.27, 838–844 (1996). ArticleCASPubMed Google Scholar
Houck, K.A. et al. The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol. Endocrinol.5, 1806–1814 (1991). ArticleCASPubMed Google Scholar
Tischer, E. et al. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J. Biol. Chem.266, 11947–11954 (1991). ArticleCASPubMed Google Scholar
Ferrara, N. & Henzel, W.J. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem. Biophys. Res. Commun.161, 851–858 (1989). ArticleCASPubMed Google Scholar
Houck, K.A., Leung, D.W., Rowland, A.M., Winer, J. & Ferrara, N. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J. Biol. Chem.267, 26031–26037 (1992). ArticleCASPubMed Google Scholar
Park, J.E., Keller, H.-A. & Ferrara, N. The vascular endothelial growth factor isoforms (VEGF): differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol. Biol. Cell4, 1317–1326 (1993). ArticleCASPubMedPubMed Central Google Scholar
Keyt, B.A. et al. The carboxyl-terminal domain (111–165) of vascular endothelial growth factor is critical for its mitogenic potency. J. Biol. Chem.271, 7788–7795 (1996). ArticleCASPubMed Google Scholar
Carmeliet, P. et al. Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelila growth factor isoforms VEGF164 and VEGF188 . Nat. Med.5, 495–502 (1999). ArticleCASPubMed Google Scholar
Ruhrberg, C. et al. Spatially restricted patterning cues provided by heparin-binding VEGFA control blood vessel branching morphogenesis. Genes Dev.16, 2684–2698 (2002). ArticleCASPubMedPubMed Central Google Scholar
Dor, Y., Porat, R. & Keshet, E. Vascular endothelial growth factor and vascular adjustments to perturbations in oxygen homeostasis. Am. J. Physiol.280, C1367–C1374 (2001). ArticleCAS Google Scholar
Semenza, G. Signal transduction to hypoxia-inducible factor 1. Biochem. Pharmacol.64, 993–998 (2002). ArticleCASPubMed Google Scholar
Mole, D.R., Maxwell, P.H., Pugh, C.W. & Ratcliffe, P.J. Regulation of HIF by the von Hippel-Lindau tumour suppressor: implications for cellular oxygen sensing. IUBMB Life52, 43–47 (2001). ArticleCASPubMed Google Scholar
Siemeister, G. et al. Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein. Cancer Res.56, 2299–2301 (1996). CASPubMed Google Scholar
Iliopoulos, O., Levy, A.P., Jiang, C., Kaelin, W.G. & Goldberg, M.A. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc. Natl. Acad. Sci. USA93, 10595–10599 (1996). ArticleCASPubMedPubMed Central Google Scholar
Maxwell, P.H. et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature399, 271–275 (1999). ArticleCASPubMed Google Scholar
Maxwell, P.H. & Ratcliffe, P.J. Oxygen sensors and angiogenesis. Semin. Cell Dev. Biol.13, 29–37 (2002). ArticleCASPubMed Google Scholar
Grugel, S., Finkenzeller, G., Weindel, K., Barleon, B. & Marme, D. Both v-Ha-Ras and v-Raf stimulate expression of the vascular endothelial growth factor in NIH 3T3 cells. J. Biol. Chem.270, 25915–25919 (1995). ArticleCASPubMed Google Scholar
Okada, F. et al. Impact of oncogenes in tumor angiogenesis: mutant K-ras up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells. Proc. Natl. Acad. Sci. USA95, 3609–3614 (1998). ArticleCASPubMedPubMed Central Google Scholar
Shibuya, M. et al. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase (flt) closely related to the fms family. Oncogene8, 519–527 (1990). Google Scholar
Terman, B.I. et al. Identification of a new endothelial cell growth factor receptor tyrosine kinase. Oncogene6, 1677–1683 (1991). CASPubMed Google Scholar
de Vries, C. et al. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science255, 989–991 (1992). ArticleCASPubMed Google Scholar
Gerber, H.P., Condorelli, F., Park, J. & Ferrara, N. Differential transcriptional regulation of the two VEGF receptor genes. Flt-1, but not Flk-1/KDR, is up-regulated by hypoxia. J. Biol. Chem.272, 23659–23667 (1997). ArticleCASPubMed Google Scholar
Park, J.E., Chen, H.H., Winer, J., Houck, K.A. & Ferrara, N. Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J. Biol. Chem.269, 25646–25654 (1994). ArticleCASPubMed Google Scholar
Olofsson, B. et al. Vascular endothelial growth factor B (VEGFB) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. Proc. Natl. Acad. Sci. USA95, 11709–11714 (1998). ArticleCASPubMedPubMed Central Google Scholar
Kendall, R.L. & Thomas, K.A. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc. Natl. Acad. Sci. USA90, 10705–10709 (1993). ArticleCASPubMedPubMed Central Google Scholar
Davis-Smyth, T., Chen, H., Park, J., Presta, L.G. & Ferrara, N. The second immunoglobulin-like domain of the VEGF tyrosine kinase receptor Flt-1 determines ligand binding and may initiate a signal transduction cascade. EMBO J.15, 4919–4927 (1996). ArticleCASPubMedPubMed Central Google Scholar
Waltenberger, J., Claesson Welsh, L., Siegbahn, A., Shibuya, M. & Heldin, C.H. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J. Biol. Chem.269, 26988–26995 (1994). ArticleCASPubMed Google Scholar
Carmeliet, P. et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat. Med.7, 575–583 (2001). ArticleCASPubMed Google Scholar
Gille, H. et al. A repressor sequence in the juxtamembrane domain of Flt-1 (VEGFR-1) constitutively inhibits VEGF-dependent PI 3 kinase activation and endothelial cell migration. EMBO J.19, 4064–4073 (2000). ArticleCASPubMedPubMed Central Google Scholar
Maru, Y., Yamaguchi, S. & Shibuya, M. Flt-1, a receptor for vascular endothelial growth factor, has transforming and morphogenic potentials. Oncogene16, 2585–2595 (1998). ArticleCASPubMed Google Scholar
Fong, G.H., Rossant, J., Gertsenstein, M. & Breitman, M.L. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature376, 66–70 (1995). ArticleCASPubMed Google Scholar
Fong, G.H., Zhang, L., Bryce, D.M. & Peng, J. Increased hemangioblast commitment, not vascular disorganization, is the primary defect in flt-1 knock-out mice. Development126, 3015–3025 (1999). ArticleCASPubMed Google Scholar
Hiratsuka, S., Minowa, O., Kuno, J., Noda, T. & Shibuya, M. Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc. Natl. Acad. Sci. USA4, 9349–9354 (1998). Article Google Scholar
Barleon, B. et al. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood87, 3336–3343 (1996). ArticleCASPubMed Google Scholar
Hiratsuka, S. et al. MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell2, 289–300 (2002). ArticleCASPubMed Google Scholar
Hattori, K. et al. Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1(+) stem cells from bone-marrow microenvironment. Nat. Med.8, 841–849 (2002). ArticleCASPubMedPubMed Central Google Scholar
Luttun, A. et al. Revascularization of ischemic tissues by PLGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat. Med.8, 831–840 (2002). ArticleCASPubMed Google Scholar
LeCouter, J. et al. Angiogenesis-independent endothelial protection of liver: role of VEGFR-1. Science299, 890–893 (2003). ArticleCASPubMed Google Scholar
Terman, B.I. et al. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem. Biophys. Res. Commun.187, 1579–1586 (1992). ArticleCASPubMed Google Scholar
Shalaby, F. et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature376, 62–66 (1995). ArticleCASPubMed Google Scholar
Guo, D., Jia, Q., Song, H.Y., Warren, R.S. & Donner, D.B. Vascular endothelial cell growth factor promotes tyrosine phosphorylation of mediators of signal transduction that contain SH2 domains. Association with endothelial cell proliferation. J. Biol. Chem.270, 6729–6733 (1995). ArticleCASPubMed Google Scholar
Eliceiri, B.P. et al. Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. Mol. Cell4, 915–924 (1999). ArticleCASPubMed Google Scholar
Takahashi, T., Ueno, H. & Shibuya, M. VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells. Oncogene18, 2221–2230 (1999). ArticleCASPubMed Google Scholar
Gille, H. et al. Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific VEGF mutants. J. Biol. Chem.276, 3222–3230 (2001). ArticleCASPubMed Google Scholar
Adini, A., Kornaga, T., Firoozbakht, F. & Benjamin, L.E. Placental growth factor is a survival factor for tumor endothelial cells and macrophages. Cancer Res.62, 2749–2752 (2002). CASPubMed Google Scholar
Soker, S., Fidder, H., Neufeld, G. & Klagsbrun, M. Characterization of novel vascular endothelial growth factor (VEGF) receptors on tumor cells that bind VEGF165 via its exon 7-encoded domain. J. Biol. Chem.271, 5761–5767 (1996). ArticleCASPubMed Google Scholar
Soker, S., Takashima, S., Miao, H.Q., Neufeld, G. & Klagsbrun, M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell92, 735–745 (1998). ArticleCASPubMed Google Scholar
Neufeld, G. et al. The neuropilins: multifunctional semaphorin and VEGF receptors that modulate axon guidance and angiogenesis. Trends Cardiovasc. Med.12, 13–19 (2002). ArticleCASPubMed Google Scholar
Kawasaki, T. et al. A requirement for neuropilin-1 in embryonic vessel formation, Development126, 4895–4902 (1999). ArticleCASPubMed Google Scholar
Lee, P. et al. Neuropilin-1 is required for vascular development and is a mediator of VEGF-dependent angiogenesis in zebrafish. Proc. Natl. Acad. Sci. USA99, 10470–10475 (2002). ArticleCASPubMedPubMed Central Google Scholar
Carmeliet, P. et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature380, 435–439 (1996). ArticleCASPubMed Google Scholar
Ferrara, N. et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature380, 439–442 (1996). ArticleCASPubMed Google Scholar
Bellomo, D. et al. Mice lacking the vascular endothelial growth factor-B gene (Vegfb) have smaller hearts, dysfunctional coronary vasculature, and impaired recovery from cardiac ischemia. Circ. Res.86, E29–E35 (2000). ArticleCASPubMed Google Scholar
Kitamoto, Y., Tokunaga, H. & Tomita, K. Vascular endothelial growth factor is an essential molecule for mouse kidney development: glomerulogenesis and nephrogenesis. J. Clin. Invest.99, 2351–2357 (1997). ArticleCASPubMedPubMed Central Google Scholar
Eremina, V. et al. Glomerular-specific alterations of VEGFA expression lead to distinct congenital and acquired renal diseases. J. Clin. Invest.111, 707–716 (2003). ArticleCASPubMedPubMed Central Google Scholar
Ryan, A.M. et al. Preclinical safety evaluation of rhuMAbVEGF, an antiangiogenic humanized monoclonal antibody. Toxicol. Pathol.27, 78–86 (1999). ArticleCASPubMed Google Scholar
Poole, A.R. The growth plate: cellular physiology, cartilage assembly and mineralization. in Cartilage: Molecular Aspects (eds. Hall, B.K. & Newman, S.A.) 179–211 (CRC Press, Boca Raton, Florida, 1991). Google Scholar
Gerber, H.P. et al. VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat. Med.5, 623–628 (1999). ArticleCASPubMed Google Scholar
Haigh, J.J., Gerber, H.P., Ferrara, N. & Wagner, E.F. Conditional inactivation of VEGFA in areas of collagen2a1 expression results in embryonic lethality in the heterozygous state. Development127, 1445–1453 (2000). ArticleCASPubMed Google Scholar
Zelzer, E. et al. Skeletal defects in VEGF(120/120) mice reveal multiple roles for VEGF in skeletogenesis. Development129, 1893–1904 (2002). ArticleCASPubMed Google Scholar
Goede, V., Schmidt, T., Kimmina, S., Kozian, D. & Augustin, H.G. Analysis of blood vessel maturation processes during cyclic ovarian angiogenesis. Lab. Invest.78, 1385–1394 (1998). CASPubMed Google Scholar
Phillips, H.S., Hains, J., Leung, D.W. & Ferrara, N. Vascular endothelial growth factor is expressed in rat corpus luteum. Endocrinology127, 965–967 (1990). ArticleCASPubMed Google Scholar
Ferrara, N. et al. Vascular endothelial growth factor is essential for corpus luteum angiogenesis. Nat. Med.4, 336–340 (1998). ArticleCASPubMed Google Scholar
Fraser, H.M. et al. Suppression of luteal angiogenesis in the primate after neutralization of vascular endothelial growth factor. Endocrinology141, 995–1000 (2000). ArticleCASPubMed Google Scholar
Zimmermann, R.C. et al. Short-term administration of antivascular endothelial growth factor antibody in the late follicular phase delays follicular development in the rhesus monkey. J. Clin. Endocrinol. Metab.86, 768–772 (2001). CASPubMed Google Scholar
LeCouter, J. et al. Identification of an angiogenic mitogen selective for endocrine gland endothelium. Nature412, 877–884 (2001). ArticleCASPubMed Google Scholar
LeCouter, J., Lin, R. & Ferrara, N. Endocrine gland-derived VEGF and the emerging hypothesis of organ-specific regulation of angiogenesis. Nat. Med.8, 913–917 (2002). ArticleCASPubMed Google Scholar
Ferrara, N. et al. Differential expression of the angiogenic factor genes VEGF and EG-VEGF in normal and polycystic human ovaries. Am. J. Path.162, 1881–1893 (2003). ArticleCASPubMedPubMed Central Google Scholar
Kim, K.J. et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature362, 841–844 (1993). ArticleCASPubMed Google Scholar
Fukumura, D. et al. Tumor induction of VEGF promoter activity in stromal cells. Cell94, 715–725 (1998). ArticleCASPubMed Google Scholar
Gerber, H.P., Kowalski, J., Sherman, D., Eberhard, D.A. & Ferrara, N. Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor. Cancer Res.60, 6253–6258 (2000). CASPubMed Google Scholar
Tsuzuki, Y. et al. Vascular endothelial growth factor (VEGF) modulation by targeting hypoxia-inducible factor-1α—> hypoxia response element—> VEGF cascade differ entially regulates vascular response and growth rate in tumors, Cancer Res.60, 6248–6252 (2000). CASPubMed Google Scholar
Inoue, M., Hager, J.H., Ferrara, N., Gerber, H.P. & Hanahan, D. VEGFA has a critical, nonredundant role in angiogenic switching and pancreatic β cell carcinogenesis. Cancer Cell.1, 193–202 (2002). ArticleCASPubMed Google Scholar
Klement, G. et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J. Clin. Invest.105, R15–R24 (2000). ArticleCASPubMedPubMed Central Google Scholar
Lee, C.G. et al. Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res.60, 5565–5570 (2000). CASPubMed Google Scholar
Presta, L.G. et al. Humanization of an anti-VEGF monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res.57, 4593–4599 (1997). CASPubMed Google Scholar
Prewett, M. et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis. Cancer Res.59, 5209–5218 (1999). CASPubMed Google Scholar
Wood, J.M. et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res.60, 2178–2189 (2000). CASPubMed Google Scholar
Kabbinavar, F. et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J. Clin. Oncol.21, 60–65 (2003). ArticleCASPubMed Google Scholar
Yang, J.C. et al. A randomized trial of bevacizumab (anti-VEGF antibody) in metastatic renal cancer. N. Engl. J. Med. (in the press).
Gerber, H.P. & Ferrara, N. The role of VEGF in normal and neoplastic hematopoiesis. J. Mol. Med.81, 20–31 (2003). ArticleCASPubMed Google Scholar
Smolich, B.D. et al. The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemi blasts. Blood97, 1413–1421 (2001). ArticleCASPubMed Google Scholar
Dias, S. et al. Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. J. Clin. Invest.106, 511–521 (2000). ArticleCASPubMedPubMed Central Google Scholar
Garner, A. Vascular diseases. in Pathobiology of Ocular Disease 2nd edn. (eds. Garner, A. & Klintworth, G.K.) 1625–1710 (Marcel Dekker, New York, 1994). Google Scholar
Aiello, L.P. et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N. Engl. J. Med.331, 1480–1487 (1994). ArticleCASPubMed Google Scholar
Malecaze, F. et al. Detection of vascular endothelial growth factor mRNA and vascular endothelial growth factor-like activity in proliferative diabetic retinopathy. Arch. Ophthalmol.112, 1476–1482 (1994). ArticleCASPubMed Google Scholar
Aiello, L.P. et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc. Natl. Acad. Sci. USA92, 10457–10461 (1995). ArticleCASPubMedPubMed Central Google Scholar
Adamis, A.P. et al. Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch. Ophthalmol.114, 66–71 (1996). ArticleCASPubMed Google Scholar
Chen, Y. et al. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. J. Mol. Biol.293, 865–881 (1999). ArticleCASPubMed Google Scholar
Ruckman, J. et al. 2'-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J. Biol. Chem.273, 20556–20567 (1998). ArticleCASPubMed Google Scholar
Krzystolik, M.G. et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch. Ophthalmol.120, 338–346 (2002). ArticleCASPubMed Google Scholar
Detmar, M. et al. Keratinocyte-derived vascular permeability factor (vascular endothelial growth factor) is a potent mitogen for dermal microvascular endothelial cells. J. Invest. Dermatol.105, 44–50 (1995). ArticleCASPubMed Google Scholar
Detmar, M. et al. Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice. J. Invest. Dermatol.111, 1–6 (1998). ArticleCASPubMed Google Scholar
Kovacs, Z., Ikezaki, K., Samoto, K., Inamura, T. & Fukui, M. VEGF and flt. Expression time kinetics in rat brain infarct. Stroke27, 1865–1872 (1996). ArticleCASPubMed Google Scholar
van Bruggen, N. et al. VEGF antagonism reduces edema formation and tissue damage after ischemia/reperfusion injury in the mouse brain. J. Clin. Invest.104, 1613–1620 (1999). ArticleCASPubMedPubMed Central Google Scholar
Paul, R. et al. Src deficiency or blockade of Src activity in mice provides cerebral protection following stroke. Nat. Med.7, 222–227 (2001). ArticleCASPubMed Google Scholar
McLaren, J. et al. Vascular endothelial growth factor is produced by peritoneal fluid macrophages in endometriosis and is regulated by ovarian steroids. J. Clin. Invest.98, 482–489 (1996). ArticleCASPubMedPubMed Central Google Scholar
Maynard, S.E. et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J. Clin. Invest.111, 649–658 (2003). ArticleCASPubMedPubMed Central Google Scholar
Kerbel, R. & Folkman, J. Clinical translation of angiogenesis inhibitors. Nat. Rev. Cancer2, 727–739 (2002). ArticleCASPubMed Google Scholar
Henry, T.D. et al. The VIVA trial: Vascular endothelial growth factor in ischemia for vascular angiogenesis. Circulation107, 1359–1365 (2003). ArticleCASPubMed Google Scholar
Makinen, K. et al. Increased vascularity detected by digital subtraction angiography after VEGF gene transfer to human lower limb artery: a randomized, placebo-controlled, double-blinded phase II study. Mol. Ther.6, 127–133 (2002). ArticleCASPubMed Google Scholar
Dor, Y. et al. Conditional switching of VEGF provides new insights into adult neovascularization and pro-angiogenic therapy. EMBO J.21, 1939–1947 (2002). ArticleCASPubMedPubMed Central Google Scholar
Street, J. et al. Vascular endothelial growth factor stimulates bone repair by promoting angiogenesis and bone turnover. Proc. Natl. Acad. Sci. USA99, 9656–9661 (2002). ArticleCASPubMedPubMed Central Google Scholar